Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary

Organogenesis Holdings

06/08/2026 22:02

Organogenesis Holdings Inc. ORGO.OQ reported a quarterly adjusted loss of 73 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -10 cents.  The mean expectation of two analysts for the quarter was for a loss of 35 cents per share. Wall Street expected results to range from -40 cents to -30 cents per share.
Revenue fell 56.7% to $43.76 million from a year ago; analysts expected $54.25 million. 
Organogenesis Holdings Inc.'s reported EPS for the quarter was a loss of 77 cents​.
The company reported a quarterly loss of $99.34 million.
Organogenesis Holdings Inc. shares had fallen by 2.5% this quarter and lost 54.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 218.2% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Organogenesis Holdings Inc. is $3.00, about 21% above its last closing price of $2.37
This summary was machine generated from LSEG data August 6 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.35
-0.73
Missed
Mar. 31 2026 
-0.31
-0.41
Missed
Dec. 31 2025 
0.21
0.31
Beat
Sep. 30 2025 
0.06
0.15
Beat